Agilus Diagnostics, in collaboration with Sebia, has launched the cutting-edge Anti-MCV (anti–mutated citrullinated vimentin) antibody test in India. This advanced test significantly enhances the early detection of rheumatoid arthritis (RA), especially in patients who test negative for conventional markers like anti-CCP (cyclic citrullinated peptides) and rheumatoid factor (RF).
Rheumatoid arthritis (RA), one of the most common autoimmune disorders, affects approximately 0.5–1% of the Indian population, with prevalence expected to rise due to increased awareness and improved diagnostic capabilities .
A groundbreaking antibody test developed by Sebia, the anti-MCV (anti–mutated citrullinated vimentin) test, is redefining the early diagnosis and clinical management of rheumatoid arthritis (RA), especially in patients who remain undiagnosed using conventional methods.
The anti-MCV test detects autoantibodies against a mutated form of the vimentin protein, commonly found in the synovial fluid of patients with rheumatoid arthritis (RA). It has emerged as a highly sensitive and specific biomarker, particularly valuable for identifying RA in individuals who test negative for conventional markers such as anti-CCP and rheumatoid factor (RF). Studies have shown that anti-MCV can be positive even in the absence of traditional markers, especially in patients presenting with clinical signs and symptoms of RA. Furthermore, anti-MCV positivity may precede the clinical onset of RA by up to 24 months, particularly in individuals with a strong family history, making it a powerful tool for early detection and intervention.
